We can expect an update on the VAC trials within a month, maybe less, if recruitment has progressed a bit faster than planned. There ought to be 17 or 18 enrollees in the trials by now, and a few ought to have completed treatment.
Full enrollment ought to be achieved within the next two or three weeks, at which point the company has indicated that the market would be updated.
The trial ought to be fully complete by mid September, so early October seems a good bet for a full report. You can be sure that if results are positive, a commercialization strategy will be implemented forthwith.
CZD Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
